Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Focal segmental glomerular sclerosis urine degradome pilot study

ABSTRACT: Pilot urine peptidome study to evaluate Proteasix tool to predict proteolytic activity associated with nephrotic syndrome disease.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Michael L. Merchant, PhD

PROVIDER: MSV000084084 | MassIVE | Fri Jul 12 12:40:00 BST 2019

SECONDARY ACCESSION(S): PXD014595

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

DNA methylation profiling of genomic DNA isolated from urine in Diabetic Chronic-Kidney Disease: a pilot study

Project description:Genome wide DNA methylation profiling of urine and blood samples from patients with diabetic chronic kidney disease. The Illumina Infinium MethylationEPIC BeadChip kit was used to obtain DNA methylation profiles across approximately 850,000 CpGs. Samples included two urine and four buffy coat samples from adults with diabetic chronic kidney disease.

2017-11-16 | GSE106902 | GEO

Urine single cell RNA-sequencing in focal segmental glomerulosclerosis reveals inflammatory signatures in immune cells and podocytes

Project description:The diagnosis of focal segmental glomerulosclerosis (FSGS) requires a renal biopsy which is invasive and can be problematic in children and in some adults. We used single cell RNA-sequencing to explore disease-related cellular signatures in 17 urine samples from 12 FSGS subjects. We identified immune cells in urine predominantly monocytes and renal epithelial cells including podocytes. Analysis revealed M1 and M2 monocyte subsets and podocytes showing increased expression of genes involved in epithelial-to-mesenchymal transition (EMT). We confirmed M1 and M2 gene signatures using published monocyte/macrophage data from lupus nephritis and cancer. Using renal transcriptomic data from the Nephrotic Syndrome Study Network (NEPTUNE) we found that urine immune and EMT signature genes also showed higher expression in FSGS biopsies compared to minimal change disease biopsies. These results suggest that urine cell profiling may serve as a diagnostic and prognostic tool in nephrotic syndrome and may assist in identifying novel biomarkers and developing personalized therapeutic strategies.

2021-12-07 | GSE176465 | GEO

Minimal change disease and focal segmental sclerosis in urine

Project description:This study will investigate if urine metabolomics can help understand the pathophysiology of glomerular diseases.

2015-02-12 | ST000329 | MetabolomicsWorkbench

Glomerular tissue extra-cellular proteome in focal segemental glomerular sclerosis

Project description:Glomeruli were isolated from formalin-fixed paraffin embedded (FFPE) preserved human kidney biopsies using laser capture micro-dissection. Isolated tissue was de-cellularized by extraction using an ammonium hydroxide/NP-40 protocol. The residual extra-cellular fraction was analyzed by 1-dimensional C18 RP LCMS.

2019-07-12 | MSV000084083 | MassIVE

Urine-derived podocytes from Alport patients as a model for glomerular filtration barrier defects

Project description:Alport syndrome (AS) is a genetic defect involving mutations of collagen IV α3, α4 or α5 genes, resulting in distinctive clinical features: kidney disease, hearing loss and eye abnormalities. Podocytes are responsible of production and correct assembly of the collagen IV isoforms, however, specific alterations of podocyte phenotype are currently scarce. We here generated immortalised AS urine-derived podocyte from three different patients. AS podocytes expressed a typical podocyte signature when compared to normal urine-derived podocytes, with comparable expression of podocyte markers. Each AS cell line showed a collagen IV profile that reflected the typical patient mutation. Furthermore, by RNA-sequencing 348 genes were found differentially expressed in Alport podocytes. Gene Ontology analysis underlined enrichment in genes involved in cell motility, adhesion, survival and angiogenesis. In parallel, AS podocyte motility was reduced. In conclusion, our data clearly indicate that AS podocytes display altered features connected but distinct from the collagen alterations.

2020-06-18 | GSE134011 | GEO

Urine

Project description:Urine Raw sequence reads

| PRJNA850668 | ENA

urine metagenome

Project description:source-separated urine Metagenome

| PRJNA399057 | ENA

Pilot Study Evaluating Everolimus Molecular Mechanisms in Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD)

Project description:Treatment resistant epilepsy in tuberous sclerosis complex (TSC) and some focal cortical dysplasias (FCDs) are associated with dysfunctional mammalian target of rapamycin (mTOR) signaling. This can upregulate cell growth and proliferation, with increased downstream ribosomal S6 protein phosphorylation (phospho-S6). mTOR inhibitors are used in TSC, the archetypal mTORopathy, to reduce tumor growth or seizure frequency. Preclinical studies in FCD support a potential role in suppressing seizures. This pilot study sought to evaluate the safety of the mTOR inhibitor everolimus in treatment-resistant (failure of > 2 anti-seizure medications) TSC and FCD patients undergoing surgical resection and to assess changes in mTOR signaling and molecular pathways.

2021-12-10 | MSV000088551 | MassIVE

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra.

Project description: Not available

| S-EPMC8720665 | biostudies-literature

Fragile X urine microRNA profiling

Project description:MicroRNA (miRNA) biomarkers for fragile X syndrome were searched by urine microRNA (miRNA) profiling using deep sequencing. The urine miRNA profile of twin boys who shared the same environment but one had a FXS full mutation and the other carried a premutation allele was compared based on the similar sequence reads. The urine of twin boys showed 28 differentiatially regulated miRNAs when 219 reliable identified miRNAs were compared.

2020-03-30 | GSE143347 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data